Isoniazid pharmacokinetics, pharmacodynamics, and dosing in South African infants

Therapeutic Drug Monitoring

Volumn 34, Issue 4, 2012, Pages 446-451

  Kiser, Jennifer J ^a   Zhu, Rui ^b   D'Argenio, David Z ^b   Cotton, Mark F ^c   Bobat, Raziya ^d   McSherry, George D ^e   Madhi, Shabir A ^f   Carey, Vincent J ^g   Seifart, Heiner I ^c   Werely, Cedric J ^c   Fletcher, Courtney V ^h  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c STELLENBOSCH UNIVERSITY   (South Africa)

^d UNIVERSITY OF KWAZULU NATAL   (South Africa)

^e PENN STATE COLLEGE OF MEDICINE   (United States)

^f UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^g HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^h UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

children; dosing; infants; isoniazid; pharmacokinetics

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; ISONIAZID;

AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CHILD; CONTROLLED STUDY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG TOLERABILITY; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; PERINATAL INFECTION; PRESCHOOL CHILD; PRIORITY JOURNAL; SOUTH AFRICA; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; AREA UNDER CURVE; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; FEMALE; HIV INFECTIONS; HUMANS; INFANT; ISONIAZID; MALE; MYCOBACTERIUM TUBERCULOSIS; SOUTH AFRICA; TUBERCULOSIS;

EID: 84863826179     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31825c4bc3     Document Type: Article

References (26)

1. Swaminathan S, Rekha B. Pediatric tuberculosis: global overview and challenges. Clin Infect Dis. 2010;50(suppl 3):S184-S194.
2. Weber WW, Hein DW. Clinical pharmacokinetics of isoniazid. Clin Pharmacokinet. 1979;4:401-422. (Pubitemid 10210049)
3. Walker K, Ginsberg G, Hattis D, et al. Genetic polymorphism in N-acetyltransferase (NAT): population distribution of NAT1 and NAT2 activity. J Toxicol Environ Health. 2009;12:440-472.
4. Preziosi P. Isoniazid: metabolic aspects and toxicological correlates. Curr Drug Metab. 2007;8:839-851. (Pubitemid 350238914)
5. Donald PR, Sirgel FA, Venter A, et al. The influence of human N-acetyltransferase genotype on the early bactericidal activity of isoniazid. Clin Infect Dis. 2004;39:1425-1430. (Pubitemid 39518202)
6. Madhi SA, Nachman S, Violari A, et al. Primary isoniazid prophylaxis against tuberculosis in HIV-exposed children. N Engl J Med. 2011;365: 21-31.
7. Seifart HI, Gent WL, Parkin DP, et al. High-performance liquid chromatographic determination of isoniazid, acetylisoniazid and hydrazine in biological fluids. J Chromatogr. 1995;674:269-275. (Pubitemid 26005467)
8. Schaaf HS, Parkin DP, Seifart HI, et al. Isoniazid pharmacokinetics in children treated for respiratory tuberculosis. Arch Dis Child. 2005;90:614-618. (Pubitemid 40780724)
9. Zhu R, Kiser JJ, Mitchell C, et al. The pharmacogenetics of NAT2 enzyme maturation in perinatally HIV exposed infants receiving isoniazid. J Clin Pharmacol. 2012;52:511-519.
10. Yan J, Fine J. Estimating equations for association structures. Stat Med. 2004;23:859-874; discussion 875-877,879-880.
11. Hojsgaard S, Halekoh U, Yan J. The R Package geepack for generalized estimating equations. J Stat Software. 2005;15:1-11.
12. Division of Aids (DAIDS). Table for grading severity of pediatric (> 3 months of age) adverse experiences. 1994. Available at: http://hsc.unm.edu/som/ gcrc/ftp/ToxicityTables-Pediatric-Over3monthsAge.pdf. Accessed February 13, 2012.
13. Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs. 2002;62:2169-2183. (Pubitemid 35252827)
14. Chideya S, Winston CA, Peloquin CA, et al. Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana. Clin Infect Dis. 2009;48:1685-1694.
15. McIlleron H, Willemse M, Werely CJ, et al. Isoniazid plasma concentrations in a cohort of South African children with tuberculosis: implications for international pediatric dosing guidelines. Clin Infect Dis. 2009;48:1547-1553.
16. Donald PR, Parkin DP, Seifart HI, et al. The influence of dose and N-acetyltransferase-2 (NAT2) genotype and phenotype on the pharmacokinetics and pharmacodynamics of isoniazid. Eur J Clin Pharmacol. 2007;63:633-639. (Pubitemid 46911342)
17. Wilkins JJ, Langdon G, McIlleron H, et al. Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patients. Br J Clin Pharmacol. 2011;72:51-62.
18. The National Center for Health Statistics and the National Center for Chronic Disease Prevention and Health Promotion. 2000. Available at: https://www.cdc.gov/growthcharts/. Accessed May 9, 2011.
19. Parkin DP, Vandenplas S, Botha FJ, et al. Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis. Am J Respir Crit Care Med. 1997;155:1717-1722. (Pubitemid 27216683)
20. Kergueris MF, Bourin M, Larousse C. Pharmacokinetics of isoniazid: influence of age. Eur J Clin Pharmacol. 1986;30:335-340. (Pubitemid 16084210)
21. Rey E, Gendrel D, Treluyer JM, et al. Isoniazid pharmacokinetics in children according to acetylator phenotype. Fundam Clin Pharmacol. 2001;15:355-359. (Pubitemid 34037826)
22. Zar HJ, Cotton MF, Strauss S, et al. Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial. BMJ. 2007;334:136.
23. Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental pharmacology - drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349:1157-1167. (Pubitemid 37122329)
24. National Tuberculosis Control Programme Practical Guidelines 2000. 2000. Available at: http://www.doh.gov.za/tb/index.html. Accessed December 11, 2010.
25. South African National Tuberculosis Guidelines 2008. 2008. Available at: http://hivfshealth.org/document/2011/03/14/national-tuberculosis-management- guidelines. Accessed February 13, 2012.
26. Treatment of Tuberculosis: American Thoracic Society, CDC, and Infectious Diseases Society of America. 2003. Available at: http://www.cdc.gov/mmwr/ preview/mmwrhtml/rr5211a1.htm. Accessed December 11, 2010.